STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer. / Taber, Ann; Park, Youngrok; Lelo, Alana; Prip, Frederik; Xiao, Jerry; Berry, Deborah L; Chaldekas, Krysta; Jensen, Jørgen Bjerggaard; Philips, George; Kim, Jung-Sik; Harris, Brent T; Dyrskjøt, Lars; Waldman, Todd.

I: Urologic Oncology: Seminars and Original Investigations, Bind 39, Nr. 7, 07.2021, s. 438.e1-438.e9.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Taber, A, Park, Y, Lelo, A, Prip, F, Xiao, J, Berry, DL, Chaldekas, K, Jensen, JB, Philips, G, Kim, J-S, Harris, BT, Dyrskjøt, L & Waldman, T 2021, 'STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer', Urologic Oncology: Seminars and Original Investigations, bind 39, nr. 7, s. 438.e1-438.e9. https://doi.org/10.1016/j.urolonc.2021.02.007

APA

Taber, A., Park, Y., Lelo, A., Prip, F., Xiao, J., Berry, D. L., Chaldekas, K., Jensen, J. B., Philips, G., Kim, J-S., Harris, B. T., Dyrskjøt, L., & Waldman, T. (2021). STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 39(7), 438.e1-438.e9. https://doi.org/10.1016/j.urolonc.2021.02.007

CBE

Taber A, Park Y, Lelo A, Prip F, Xiao J, Berry DL, Chaldekas K, Jensen JB, Philips G, Kim J-S, Harris BT, Dyrskjøt L, Waldman T. 2021. STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations. 39(7):438.e1-438.e9. https://doi.org/10.1016/j.urolonc.2021.02.007

MLA

Taber, Ann o.a.. "STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer". Urologic Oncology: Seminars and Original Investigations. 2021, 39(7). 438.e1-438.e9. https://doi.org/10.1016/j.urolonc.2021.02.007

Vancouver

Taber A, Park Y, Lelo A, Prip F, Xiao J, Berry DL o.a. STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations. 2021 jul;39(7):438.e1-438.e9. https://doi.org/10.1016/j.urolonc.2021.02.007

Author

Taber, Ann ; Park, Youngrok ; Lelo, Alana ; Prip, Frederik ; Xiao, Jerry ; Berry, Deborah L ; Chaldekas, Krysta ; Jensen, Jørgen Bjerggaard ; Philips, George ; Kim, Jung-Sik ; Harris, Brent T ; Dyrskjøt, Lars ; Waldman, Todd. / STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer. I: Urologic Oncology: Seminars and Original Investigations. 2021 ; Bind 39, Nr. 7. s. 438.e1-438.e9.

Bibtex

@article{dc3073ede8d24500a0f4ca24b57039c8,
title = "STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer",
abstract = "OBJECTIVE: Improvements to bladder cancer risk stratification guidelines are needed to better tailor post-operative surveillance and adjuvant therapy to individual patients. We previously identified STAG2 as a commonly mutated tumor suppressor gene in bladder cancer and an independent predictor of progression in NMIBC. Here we test the value of combining STAG2 immunostaining with other risk stratification biomarkers in NMIBC, and as an individual biomarker in MIBC.MATERIALS AND METHODS: STAG2 immunohistochemistry was performed on a progressor-enriched cohort of tumors from 297 patients with NMIBC, and on tumors from 406 patients with MIBC from Aarhus University Hospital in Denmark. Survival analysis was performed using Kaplan-Meier survival analysis, the log rank test, and Cox proportional hazards models.RESULTS: STAG2-negative low-grade NMIBC tumors were 2.5 times less likely to progress to muscle invasion than STAG2-positive low-grade NMIBC tumors (Log-rank test, P = 0.008). In a composite group of patients with AUA intermediate and high-risk NMIBC tumors, STAG2-negative tumors were less likely to progress (Log-rank test, P = 0.02). In contrast to NMIBC, we show that STAG2 is not useful as a prognostic biomarker in MIBC.CONCLUSIONS: STAG2 immunostaining can be used to subdivide low-grade NMIBC tumors into two groups with substantially different risks of disease progression. Furthermore, STAG2 immunostaining may be useful to enhance NMIBC risk stratification guidelines, though larger cohorts are needed to solidify this conclusion in individual risk groups. STAG2 is not useful as a biomarker in MIBC. Further study of the use of STAG2 immunostaining as a biomarker for predicting the clinical behavior in NMIBC is warranted.",
author = "Ann Taber and Youngrok Park and Alana Lelo and Frederik Prip and Jerry Xiao and Berry, {Deborah L} and Krysta Chaldekas and Jensen, {J{\o}rgen Bjerggaard} and George Philips and Jung-Sik Kim and Harris, {Brent T} and Lars Dyrskj{\o}t and Todd Waldman",
note = "Copyright {\textcopyright} 2021 Elsevier Inc. All rights reserved.",
year = "2021",
month = jul,
doi = "10.1016/j.urolonc.2021.02.007",
language = "English",
volume = "39",
pages = "438.e1--438.e9",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier",
number = "7",

}

RIS

TY - JOUR

T1 - STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer

AU - Taber, Ann

AU - Park, Youngrok

AU - Lelo, Alana

AU - Prip, Frederik

AU - Xiao, Jerry

AU - Berry, Deborah L

AU - Chaldekas, Krysta

AU - Jensen, Jørgen Bjerggaard

AU - Philips, George

AU - Kim, Jung-Sik

AU - Harris, Brent T

AU - Dyrskjøt, Lars

AU - Waldman, Todd

N1 - Copyright © 2021 Elsevier Inc. All rights reserved.

PY - 2021/7

Y1 - 2021/7

N2 - OBJECTIVE: Improvements to bladder cancer risk stratification guidelines are needed to better tailor post-operative surveillance and adjuvant therapy to individual patients. We previously identified STAG2 as a commonly mutated tumor suppressor gene in bladder cancer and an independent predictor of progression in NMIBC. Here we test the value of combining STAG2 immunostaining with other risk stratification biomarkers in NMIBC, and as an individual biomarker in MIBC.MATERIALS AND METHODS: STAG2 immunohistochemistry was performed on a progressor-enriched cohort of tumors from 297 patients with NMIBC, and on tumors from 406 patients with MIBC from Aarhus University Hospital in Denmark. Survival analysis was performed using Kaplan-Meier survival analysis, the log rank test, and Cox proportional hazards models.RESULTS: STAG2-negative low-grade NMIBC tumors were 2.5 times less likely to progress to muscle invasion than STAG2-positive low-grade NMIBC tumors (Log-rank test, P = 0.008). In a composite group of patients with AUA intermediate and high-risk NMIBC tumors, STAG2-negative tumors were less likely to progress (Log-rank test, P = 0.02). In contrast to NMIBC, we show that STAG2 is not useful as a prognostic biomarker in MIBC.CONCLUSIONS: STAG2 immunostaining can be used to subdivide low-grade NMIBC tumors into two groups with substantially different risks of disease progression. Furthermore, STAG2 immunostaining may be useful to enhance NMIBC risk stratification guidelines, though larger cohorts are needed to solidify this conclusion in individual risk groups. STAG2 is not useful as a biomarker in MIBC. Further study of the use of STAG2 immunostaining as a biomarker for predicting the clinical behavior in NMIBC is warranted.

AB - OBJECTIVE: Improvements to bladder cancer risk stratification guidelines are needed to better tailor post-operative surveillance and adjuvant therapy to individual patients. We previously identified STAG2 as a commonly mutated tumor suppressor gene in bladder cancer and an independent predictor of progression in NMIBC. Here we test the value of combining STAG2 immunostaining with other risk stratification biomarkers in NMIBC, and as an individual biomarker in MIBC.MATERIALS AND METHODS: STAG2 immunohistochemistry was performed on a progressor-enriched cohort of tumors from 297 patients with NMIBC, and on tumors from 406 patients with MIBC from Aarhus University Hospital in Denmark. Survival analysis was performed using Kaplan-Meier survival analysis, the log rank test, and Cox proportional hazards models.RESULTS: STAG2-negative low-grade NMIBC tumors were 2.5 times less likely to progress to muscle invasion than STAG2-positive low-grade NMIBC tumors (Log-rank test, P = 0.008). In a composite group of patients with AUA intermediate and high-risk NMIBC tumors, STAG2-negative tumors were less likely to progress (Log-rank test, P = 0.02). In contrast to NMIBC, we show that STAG2 is not useful as a prognostic biomarker in MIBC.CONCLUSIONS: STAG2 immunostaining can be used to subdivide low-grade NMIBC tumors into two groups with substantially different risks of disease progression. Furthermore, STAG2 immunostaining may be useful to enhance NMIBC risk stratification guidelines, though larger cohorts are needed to solidify this conclusion in individual risk groups. STAG2 is not useful as a biomarker in MIBC. Further study of the use of STAG2 immunostaining as a biomarker for predicting the clinical behavior in NMIBC is warranted.

U2 - 10.1016/j.urolonc.2021.02.007

DO - 10.1016/j.urolonc.2021.02.007

M3 - Journal article

C2 - 33712344

VL - 39

SP - 438.e1-438.e9

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 7

ER -